Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Theranostic Rgd@Fe3o4-Au/Gd Nps for the Targeted Radiotherapy and Mr Imaging of Breast Cancer Publisher



Amraee A1, 2 ; Alamzadeh Z2 ; Irajirad R2 ; Sarikhani A2 ; Ghaznavi H3, 4 ; Ghadiri Harvani H5 ; Mahdavi SR1 ; Shirvalilou S1, 2 ; Khoei S1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Medical Physics Department, School of Medicine, Iran University of Medical Sciences, P.O.Box: 1449614525, Tehran, Iran
  2. 2. Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
  4. 4. Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran
  5. 5. Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran

Source: Cancer Nanotechnology Published:2023


Abstract

Background: As a radiosensitizing agent in magnetic resonance imaging (MRI), gadolinium is disadvantageous in that it confers a rather high toxicity and low longitudinal comfort time (r1). We hypothesized that gadolinium when combined with gold-coated iron oxide nanoparticles (NPs), might deliver better radiosensitization in MRI-based cancer theranostics. After being synthesized ligand/receptor RGD@Fe3O4-Au/Gd nanoparticles, they were characterized via some methods, such as visible–ultraviolet spectroscopy (UV–VIS), Fourier transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and transmission electron microscope (TEM). Using relaxometry, the parameters of contrast change in T1-weighted MRI and the rate of radiation sensitivity on cancerous (MCF-7, SK-BR-3 and MDA-MB-231 (and reference (MCF-10a) breast cell lines were investigated. Results: The presence of ultra-small iron oxide, gold, gadolinium, and RGD peptide as components of the RGD@Fe3O4-Au/Gd nanocomplex was confirmed by UV–visible, FTIR, EDX and XRD tests. With a size ranging from 4.124 nm (DLS) to 15 nm (TEM), these NPs exhibited a surface charge of –45.7 mV and a magnetic saturation of 3 emu/g. The concentrations of iron, gadolinium and gold samples in the nanocomplex were 1000, 1171 and 400 parts per million (ppm), respectively. In the relaxometry test, the rates of r2/r1 and r1 NPs were 1.56 and 23.5 mM−1 s−1. The dose increase factor for targeted (RGD@Fe3O4-Au/Gd) and non-targeted (Fe3O4-Au/Gd) NPs at 6 MV and 2 Gy was 89.1 and 59.1, respectively. Conclusion: Owing to an enhanced signal-to-noise ratio (SNR), as confirmed by the MRI of RGD receptor-expressing MDA-MB-231 cells, RGD@Fe3O4-Au/Gd NPs were found to confer higher radiosensitization and an overall better performance as a novel radiosensitizer for MRI-based breast cancer theranostics than Fe3O4-Au/Gd nanocomplex. Graphical Abstract: [Figure not available: see fulltext.] © 2023, The Author(s).
Related Docs
1. Application of Nano-Radiosensitizers in Combination Cancer Therapy, Bioengineering and Translational Medicine (2023)
2. Targeted Superparamagnetic Iron Oxide Nanoparticles for Early Detection of Cancer: Possibilities and Challenges, Nanomedicine: Nanotechnology# Biology# and Medicine (2016)
3. Preparation of Methotrexate Loaded Plga Nanoparticles Coated With Pva and Poloxamer188, Nanomedicine Research Journal (2018)
4. Progress and Prospects of Magnetic Iron Oxide Nanoparticles in Biomedical Applications: A Review, Artificial Organs (2021)
5. Multimodal Cancer Cell Therapy Using Au@Fe 2 O 3 Core–Shell Nanoparticles in Combination With Photo-Thermo-Radiotherapy, Photodiagnosis and Photodynamic Therapy (2018)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (1)
Mohamad Raoufi (1)